Dexamethasone-(C\textsubscript{21}-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)

Purpose: Corticosteroids are effective in the management of a variety of disease states, such as several forms of neoplasia (leukemia and lymphoma), autoimmune conditions, and severe inflammatory responses. Molecular strategies that selectively “target” delivery of corticosteroids minimize or prevents large amounts of the pharmaceutical moiety from passively diffusing into normal healthy cell populations residing within tissues and organ systems.

Materials and methods: The covalent immunopharmaceutical, dexamethasone-(C\textsubscript{21}-phosphoramide)-[anti-EGFR] was synthesized by reacting dexamethasone-21-monophosphate with a carbodiimide reagent to form a dexamethasone phosphate carbodiimide ester that was subsequently reacted with imidazole to create an amine-reactive dexamethasone-(C\textsubscript{21}-phosphoramideimidazolide) intermediate. Monoclonal anti-EGFR immunoglobulin was combined with the amine-reactive dexamethasone-(C\textsubscript{21}-phosphoramideimidazolide) intermediate, resulting in the synthesis of the covalent immunopharmaceutical, dexamethasone-(C\textsubscript{21}-phosphoramide)-[anti-EGFR]. Following spectrophotometric analysis and validation of retained epidermal growth factor receptor type 1 (EGFR)-binding avidity by cell-ELISA, the selective antineoplastic cytotoxic potency of dexamethasone-(C\textsubscript{21}-phosphoramide)-[anti-EGFR] was established by MTT-based vitality stain methodology using adherent monolayer populations of human pulmonary adenocarcinoma (A549) known to overexpress the trophic membrane receptors EGFR and insulin-like growth factor receptor type 1.

Results: The dexamethasone:IgG molar-incorporation-index for dexamethasone-(C\textsubscript{21}-phosphoramide)-[anti-EGFR] was 6.95:1 following exhaustive serial microfiltration. Cytotoxicity analysis: covalent bonding of dexamethasone to monoclonal anti-EGFR immunoglobulin did not significantly modify the ex vivo antineoplastic cytotoxicity of dexamethasone against pulmonary adenocarcinoma at and between the standardized dexamethasone equivalent concentrations of $10^{-9}$ M and $10^{-7}$ M. Rapid increases in antineoplastic cytotoxicity were observed at and between the dexamethasone equivalent concentrations of $10^{-8}$ M and $10^{-7}$ M where cancer cell death increased from 7.7% to a maximum of 64.9% (92.3%–35.1% residual survival), respectively, which closely paralleled values for “free” noncovalently bound dexamethasone.

Discussion: Organic chemistry reaction regimens were optimized to develop a multiphase synthesis regimen for dexamethasone-(C\textsubscript{21}-phosphoramide)-[anti-EGFR]. Attributes of dexamethasone-(C\textsubscript{21}-phosphoramide)-[anti-EGFR] include a high dexamethasone molar incorporation-index, lack of extraneous chemical group introduction, retained EGFR-binding avidity (“targeted” delivery properties), and potential to enhance long-term pharmaceutical moiety effectiveness.

Keywords: dexamethasone, anti-EGFR, organic chemistry reactions, synthesis, selective “targeted” delivery, covalent immunopharmaceuticals, EGFR
Introduction

Dexamethasone (8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[α]phenanthren-3-one is a corticosteroid with profound anti-inflammatory properties that are attributed to several different molecular mechanisms of action that involves inhibition of several synthesis pathways that includes 1) phospholipase-A₂ biochemical activity inhibition resulting in a diminished arachidonic acid substrate availability for prostaglandin and leukotriene synthesis; 2) NF-κB resulting in a reduced production of tumor necrosis factor-α and Th1 interleukins (eg, IL-1, IL-6, and IL-2); 3) reduced IL-5 production (IL-5 >> IL-2 inhibition); 4) suppression of IFN-γ-induced major histocompatibility antigen Type II expression accompanied by 5) an induced synthesis of endogenous IL-10 that potently exerts profound anti-inflammatory properties. Influences of dexamethasone on immune cellular function are in part related to their 6) prevention or reduction of leukocyte degranulation; 7) inhibition of macrophage phagocytosis; and 8) promotion of overt lymphocyte cytolysis. Each of these properties to a varying degree represents a justification for corticosteroid administration in the therapeutic management of the hematopoietic neoplastic conditions of leukemia and lymphoma in addition to a spectrum of autoimmune disorders. In clinical regimens for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), corticosteroids are coadministered in the cyclophosphamide–doxorubicin–vincristine–prednisone (CHOP) treatment regimen of cyclophosphamide, doxorubicin, vincristine, and prednisolone.¹

Common complications associated with corticosteroid administration include relatively rapid development of resistance in addition to substantial immunosuppression (susceptibility to septic complications) where each of these confounding disadvantages can restrict the duration of administration and limit the successful resolution of aggressive or advanced conditions of neoplastic disease. Alternatively, if a corticosteroid-like dexamethasone is covalently bound to a molecular platform-like immunoglobulin G (IgG) that possesses properties of selective binding avidity, it then becomes a molecular platform-like immunoglobulin G (IgG) that possesses properties of selective binding avidity as it pertains to viability, proliferation rate, local invasiveness, metastatic potential, and chemotherapeutic resistance (eg, P-glycoprotein coexpression).⁵⁻⁷ Trophic membrane receptor, epidermal growth factor receptor type 1 (EGFR), is overexpressed in non-small-cell lung cancer at a case frequency of 40%–80% and is particularly common in the cell types of squamous cell carcinoma and bronchoalveolar carcinoma.¹¹ Analogous to many adenocarcinoma and carcinoma cell types that overexpress EGFR and HER2/neu, conditions of leukemia and lymphoma frequently overexpress several cell differentiation antigens and receptors on their exterior surface membrane. In an effect similar to herceptin (anti-HER2/neu) and cetuximab (anti-EGFR) on adenocarcinoma and carcinoma cell types, the monoclonal IgG fractions, anti-CD20 (rituximab and ofatumumab), and anti-CD52 (alemtuzumab) suppress growth and vitality of leukemia and lymphoma, while some subtypes (chronic lymphocytic leukemia [CLL]) also can express insulin-like growth factor receptor type 1 (IGF-1R) membrane receptors.¹² Therapeutically, anti-CD20 (rituximab and ofatumumab) and anti-CD52 (alemtuzumab) have efficacy against B-CLL. Anti-CD20 (rituximab) in simultaneous combination with CHOP increases survival over CHOP alone in conditions of high-grade lymphomas.¹ In contrast to anti-HER2/neu, anti-EGFR, and anti-IGF-1R, however, the predominate mechanism by which vitality and growth of leukemia or lymphoma populations is compromised by anti-CD20 and anti-CD52 occurs through the formation of surface membrane Ag:IgG complexes that subsequently activate the endogenous-based immune mechanisms of 1) antibody-dependent cell cytotoxicity (ADCC), 2) complement-mediated cytolysis (CMC), and 3) opsonization/phagocytosis.¹³–¹⁸ Resistance to anti-CD20 and anti-CD52 may develop through multiple mechanisms, such as rapid receptor-mediated endocytosis prior to ADCC/CMC/opsonization,¹¹,¹⁹ monocyte/macrophage CD20/CD52 “shaving” (trogocytosis),²⁰ and immune evasion imposed through immunosuppressive mediators emanating from cancer cell populations.²¹,²² Interestingly, ofatumumab (anti-CD20) has been approved for B-CLL resistant to alemtuzumab and fludarabine.

Minimizing the systemic corticosteroid immunosuppression, the rapid development of corticosteroid resistance, and the propensity for IgG-based monotherapies to primarily
suppress cancer cell growth but not to exert profound potent antineoplastic cytotoxicity can be attained by molecular strategies that entail covalent bonding pharmaceuticals with a steroid motif to a biologically relevant molecular platform possessing properties of selective targeted delivery. Corticosteroids, such as dexamethasone, have previously been bound covalently to serum albumin\textsuperscript{23-25} and various carbohydrate or glycosaminoglycan analogs\textsuperscript{26-29} but the molecular design and organic chemistry reaction regimens for the synthesis of covalent dexamethasone immunopharmaceuticals have rarely if ever been described extensively in scientific literature where their efficacy has most commonly been directed toward reducing inflammatory responses.\textsuperscript{30,31} Distinct attributes of a covalent dexamethasone immunopharmaceuticals include their potential to promote and facilitate 1) continual, progressive, and selective deposition of therapeutic steroid moieties on the exterior surface membrane of targeted cell populations; 2) decreased innocent exposure and reduced distribution of steroid analogs into normal healthy cells residing within tissues and organ systems; 3) prolongation of steroid moiety plasma pharmacokinetic profiles; and 4) progressive steroid moiety accumulation within the cytosol of targeted cell populations facilitated by the active transport mechanism of ligand-initiated receptor-mediated endocytosis. The latter biological phenomenon can potentially facilitate one of the therapeutic advantages of a covalent dexamethasone immunopharmaceutical because it modulates continual selective deposition and intracellular steroid moiety accumulation that can result in achieving cytosol concentrations 8.5-fold\textsuperscript{32} to >100-fold\textsuperscript{33,34} higher than those safely attainable by simple passive diffusion of a “free” noncovalently bound steroid analog from the extravascular fluid compartment postintravenous injection at clinically relevant dosages. In corticosteroid-sensitive leukemia and lymphoma cell populations, membrane-associated antigens and receptor complexes that are uniquely or highly overexpressed and are also known to be internalized by the active transport mechanism of receptor-mediated endocytosis include CCR7,\textsuperscript{35} CXCR5,\textsuperscript{36} TNFR1 (CD120a),\textsuperscript{27} CD19,\textsuperscript{38,39} CD20,\textsuperscript{13,19} and CD52.\textsuperscript{40}

The molecular design and a corresponding organic chemistry reaction scheme have been delineated to enable a multiphase regimen for synthesizing a covalent dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-EGFR] immunocorticosteroid. Analogous organic chemistry reaction schemes have been used to synthesize the covalent immunochemotherapeutics, fludarabine-(C\textsubscript{2}-methylhydroxyphosphoramide)-[anti-IGF-1R],\textsuperscript{41} and gemcitabine-(C\textsubscript{2}-phosphoramidate)-[anti-IGF-1R]. Removal of residual unreacted dexamethasone or reagents by serial microfiltration of a highly concentrated reaction mixture formulation of dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-EGFR] was determined by standardized high-performance thin layer chromatography (HP-TLC) analysis. Lack of anti-EGFR fragmentation or IgG–IgG polymerization was established by mass separation analysis using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in combination with affinity blotting and chemiluminescent autoradiography. Retained biological activity of dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-EGFR] as a function of EGFR-binding avidity was determined by cell-ELISA utilizing monolayer populations of pulmonary adenocarcinoma (A549). Selectively targeted anti-neoplastic cytotoxicity of dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-EGFR] was then determined by the assessment of residual cell vitality/survival utilizing pulmonary adenocarcinoma (A549) as an ex vivo neoplastic disease model.

**Materials and methods**

**Covalent dexamethasone immunopharmaceutical synthesis**

**Phase I synthesis format for amine-reactive chemotherapeutic intermediates**

Dexamethasone-(C\textsubscript{21}-monophosphate) was formulated at a concentration of 3.85×10\textsuperscript{-2} M in a modified phosphate-buffered saline (PBS) buffer (phosphate 5.0 mM, NaCl 75 mM, ethylene diamine tetra-acetic acid [EDTA] 5.0 mM, pH 7.4) and reacted with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide at a 5:1 molar ratio. The Phase I and Phase II reaction mixture was then allowed to gently stir at 25°C for 10–15 minutes.

**Phase II and Phase III synthesis format for covalent dexamethasone immunochemotherapeutics utilizing an amine-reactive chemotherapeutic intermediate**

Monoclonal IgG fractions of anti-EGFR (3.0 mg, 2.0×10\textsuperscript{-5} mmol) devoid of molecular stabilizing agents were formulated in imidazole buffer (100 mM, pH 6.0) and combined at a 1:50 molar ratio with the amine-reactive dexamethasone-(C\textsubscript{21})-phosphorimidazolide intermediate generated as the end product from the Phase I synthesis reaction scheme. The Phase II reaction mixture was then gently stirred continuously for 2 hours at 25°C to maximize the synthesis yield of the Phase III covalent dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-EGFR] immunopharmaceutical end product. Residual unreacted dexamethasone was removed from the covalent dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-EGFR]
immunochemotherapeutic by exhaustive serial microfiltration (molecular weight cut-off [MWCO] = 10 kDa) and buffer exchange utilizing conventional PBS buffer (phosphate 100 mM, NaCl 150 mM, pH 7.4).

Molecular analysis and characterization of properties

Covalently bound dexamethasone content
Detection and monitoring the relative amount of residual unreacted (noncovalently bound) dexamethasone contained in the Phase III reaction end product in the form of covalent dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] immunopharmaceutical was determined by analytical-scale HP-TLC (silica gel, 250 µm thickness, UV 254 nm indicator). Sensitivity of detecting residual unreacted dexamethasone by analytical-scale HP-TLC was enhanced by analyzing highly concentrated formulations of the Phase III dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] end product and the application of standardized dexamethasone reference controls formulated at matched reference control concentrations. Individual analytical-scale HP-TLC silica gel plates were subsequently developed utilizing a mobile phase solvent system composed of propanol/ethanol/ddH$_2$O/glacial acetic acid (17:5:5:1, v/v). Detection of residual unreacted dexamethasone in dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] and standardized dexamethasone reference controls followed analytical-scale HP-TLC development was subsequently determined by direct UV illumination. Total dexamethasone concentration within the dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] following exhaustive serial microfiltration was $\geq 10^{-4}$ M which is well within the range of detection for corticosteroids$^{42}$ and chemotherapeutic agents$^{43,44}$ by analytical-scale HP-TLC analysis. Complementary methods involve combining the covalent immunopharmaceutical 1:5 (v/v) with cold methanol or cold chloroform/isopropanol (2:1, v/v) and measurement of free noncovalently bound chemotherapeutic in the resulting supernatant.

Measurement of covalently bound dexamethasone
Total individual absorbance values at 265 nm were measured for dexamethasone-C$_{21}$-monophosphate, immunoglobulin, and immunoglobulin/dexamethasone-C$_{21}$-monophosphate-standardized reference controls in addition to the covalent dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] immunopharmaceutical. Concentrations of the IgG component contained within the Phase III dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] end product and IgG standardized reference controls were measured at 660 nm utilizing a metal-dye complex reagent (Pierce 660 nm Protein Assay; Thermo Fisher Scientific, Waltham, MA, USA). Concentration of the IgG component within the Phase III end product established by measurements at 660 nm was used to calculate the corresponding 265 nm absorbance measurement. Differences between the total absorbance for dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] measured at 265 nm and the calculated 265 nm absorbance for the immunoglobulin content of dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] were then applied to calculate the total dexamethasone equivalent concentration within the Phase III covalent dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] immunopharmaceutical end product.

Mass separation analysis for the detection of polymerization and fragmentation

Covalent dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] immunoochemotherapeutic in addition to reference control anti-EGFR immunoglobulin fractions formulated at a standardized protein concentration of 60 µg/mL were combined 50/50 (v/v) with conventional SDS-PAGE sample preparation buffer (Tris/glycerol/bromphenyl blue/SDS) without 2-mercaptoethanol or boiling. Covalent dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] immunoochemotherapeutic, reference control IgG (0.9 µg/well), and a mixture of prestained molecular weight marker reference controls were then developed individually by nonreducing SDS-PAGE (11% acrylamide) performed at 100 V constant voltage at 3°C for 2.5 hours.

Detection analysis for polymerization or fragmentation

Covalent dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] immunopharmaceutical following mass/size-dependent separation by nonreducing SDS-PAGE was equilibrated in tank buffer devoid of methanol. Mass/size-separated dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] immunopharmaceutical contained within acrylamide SDS-PAGE gels was then transferred laterally onto sheets of nitrocellulose membrane at 20 V (constant voltage) for 16 hours at 2°C–3°C with the transfer manifold packed in crushed ice.

Covalent dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR] immunopharmaceutical laterally transferred onto nitrocellulose membrane was then equilibrated in Tris-buffered saline (TBS; Tris HCl 0.1 M, NaCl 150 mM, pH 7.5, 40 mL) at 4°C for 15 minutes followed by an incubation period at 2°C–3°C for 16 hours in TBS blocking
buffer (Tris 0.1 M, pH 7.4, 40 mL) containing bovine serum albumin (BSA: 5%) applied in combination with gentle horizontal agitation. Prior to further processing, nitrocellulose membranes were vigorously rinsed with TBS (Tris 0.1 M, pH 7.4, 40 mL; n=3).

Rinsed BSA-blocked nitrocellulose membranes developed for Western blot (immunodetection) analyses were incubated with horseradish peroxidase biological reagent protein G conjugate (0.25 µg/mL) at 4°C for 18 hours on a horizontal orbital shaker. Nitrocellulose membranes following vigorous rinsing in TBS (pH 7.4, 4°C, 50 mL, n=3) were incubated in blocking buffer (Tris 0.1 M, pH 7.4, with BSA 5%, 40 mL). Blocking buffer was decanted from nitrocellulose membrane blots that were again vigorously rinsed with TBS (pH 7.4, 4°C, 50 mL, n=3) before incubation with horseradish peroxidase biological reagent chemiluminescent substrate (25°C, 5–10 minutes). Under dark conditions, chemiluminescent autoradiography images were acquired by exposing radiographic film (BioMax XAR, Eastman Kodak, Rochester, NY, USA) to nitrocellulose membranes sealed within transparent ultraclear resealable plastic envelopes.

**Pulmonary adenocarcinoma (A549) cell tissue culture**

**Pulmonary adenocarcinoma ex vivo cell culture**

Pulmonary adenocarcinoma (A549: ATCC American Tissue Cell Culture) populations were propagated until monolayers were ≥85% confluent in 150 cm² tissue culture flasks containing F-12K growth media supplemented with fetal bovine serum (10%, v/v) and penicillin-streptomycin at a temperature of 37°C under a gas atmosphere of carbon dioxide (CO₂ 5%) and air (95%). Trypsin or any other biochemically active enzyme fractions were not used to facilitate the harvest of pulmonary adenocarcinoma (A549) cell suspensions for the seeding of tissue culture flasks or multiwell tissue culture plates. Growth media were not supplemented with growth factors, growth hormones, or any other type of growth stimulant. Pulmonary adenocarcinoma (A549) monolayer populations utilized for cell-ELISA analyses were uniformly propagated to a ≥85% level of confluency.

The human pulmonary adenocarcinoma/alveolar basal epithelial cell line A549 which was derived in 1972 from a 58-year-old Caucasian male, was utilized as an ex vivo model for neoplastic disease. Characteristic features and biological properties of the pulmonary adenocarcinoma (A549) cell line include 1) multidrug/chemotherapeutic resistance, 2) corticosteroid sensitivity, and 3) overexpression of membrane endogenous trophic receptors or antigenic sites. Most prominent in this regard include 1) EGFR (ErbB-1 and HER1; 170–180 kDa); 2) HER2/neu (EGFR2, ERBB2, CD340, HER2, MLN19, Neu, NGL, and TKR1); 3) IGF-1R (CD221, IGFIR, IGFR, and JTK13; 320 kDa); 4) IL-7 receptor; 5) β1-integrin (CD29, ITGB1, FNRB, GPIA, MDF2, MSK12, VLA-BETA, and VLAB; 110–130 kDa); and 6) folate receptors (100 kDa). The EGFR trophic membrane receptor is also overexpressed in non-small-cell lung cancer at a frequency of 40%–80% and most commonly in squamous cell and bronchoalveolar carcinoma subtypes. Other neoplastic cells that overexpress EGFR include Chinese hamster ovary cell (Chinese hamster ovary = 1.01×10⁵ EGFR/cell), gliomas (2.7–6.8×10⁵ EGFR/cell), epidermoid carcinoma (A431 = 2.7×10⁶/cell), and malignant glioma (U87MG = 5.0×10⁵/cell).

**Cell-ELISA detection of total external membrane-bound IgG**

Pulmonary adenocarcinoma (A549) cell suspensions were seeded into 96-well microtiter plates in aliquots of 2×10⁴ cells/well and allowed to form a confluent adherent monolayer over a period of 24–48 hours. The growth media content in each individual well was removed manually by pipette, and the cellular monolayers were then serially rinsed (n=3) with PBS followed by their stabilization onto the plastic surface of 96-well microtiter plates with parafomaldehyde (0.4% in PBS, 15 minutes). Stabilized cellular monolayers were then incubated in triplicate with gradient concentrations of covalent dexamethasone-(C₂₁-phosphoramidate)-[anti-EGFR] immunopharmaceutical formulated at IgG equivalent concentrations of 0.01 µg/mL, 0.10 µg/mL, 1.00 µg/mL, and 10.00 µg/mL in tissue culture growth media (200 µL/well). Direct contact incubation between pulmonary adenocarcinoma (A549) monolayers and dexamethasone-(C₂₁-phosphoramidate)-[anti-EGFR] was performed at 37°C over a 3-hour incubation period under a gas atmosphere of carbon dioxide (5% CO₂) and air (95%). Following serial rinsing with PBS (n=3), the development of stabilized pulmonary adenocarcinoma (A549) monolayers entailed incubation with β-galactosidase-conjugated goat antimmouse IgG (1:500 dilution) for 2 hours at 25°C with residual unbound IgG removed by serial rinsing with PBS (n=3). Final development of the cell-ELISA required serial rinsing (n=3) of stabilized pulmonary adenocarcinoma (A549) monolayers with PBS followed by incubation with ortho-nitrophenyl-β-D-galactopyranoside substrate (ONPG 100 µL/well formulated fresh at 0.9 mg/mL in PBS, pH 7.2, containing 10 mM MgCl₂ and 0.1 M 2-mercaptoethanol).
Antineoplastic cytotoxic potency evaluation in an ex vivo cancer disease model

Cell proliferation–vitality assay for measuring cytotoxic antineoplastic potency

Individual preparations of dexamethasone-(C$_7_2$$_3$$^8$-phosphoramidate)-[anti-EGFR] were formulated in growth media at final standardized dexamethasone equivalent concentrations of 10$^{-10}$ M, 10$^{-9}$ M, 10$^{-8}$ M, 10$^{-7}$ M, and 10$^{-6}$ M. Each standardized dexamethasone equivalent concentration of the covalent immunopharmaceutical was then transferred in triplicate into 96-well microtiter plates containing adherent pulmonary adenocarcinoma (A549: 2,000 cells/well) monolayers and growth media (200 µL/well). Covalent dexamethasone-(C$_7_2$$_3$$^8$-phosphoramidate)-[anti-EGFR] immunopharmaceutical was then incubated in direct contact with pulmonary adenocarcinoma (A549) monolayer populations for a period of 192 hours at 37°C under a gas atmosphere of carbon dioxide (CO$_2$ 5%) and air (95%). Following the initial 96-hour incubation period and then again 144 hours after initial challenge, pulmonary adenocarcinoma (A549) populations were replenished with fresh tissue culture media with or without covalent dexamethasone-(C$_7_2$$_3$$^8$-phosphoramidate)-[anti-EGFR] immunopharmaceutical.

Antineoplastic cytotoxic potency of dexamethasone-(C$_7_2$$_3$$^8$-phosphoramidate)-[anti-EGFR] was measured by removing all contents within the 96-well microtiter plates manually by pipette followed by serial rinsing of stabilized monolayers (n=3) with PBS followed by incubation with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide vitality stain reagent formulated in RPMI-1640 growth media devoid of pH indicator or bovine fetal calf serum (MTT: 5 mg/mL). During an incubation period of 3–4 hours at 37°C under a gas atmosphere of carbon dioxide (CO$_2$ 5%) and air (95%) the enzyme mitochondrial succinate dehydrogenase and/or NADH/NADPH-dependent cellular oxidoreductase convert MTT vitality stain reagent to navy blue formazone crystals within the cytosol of pulmonary adenocarcinoma (A549) cell populations. Contents were then removed from each of the 96 wells in the microtiter plate, followed by serial rinsing with PBS (n=3). The resulting blue intracellular formazone crystals were dissolved with dimethyl sulfoxide (DMSO) (300 µL/well) and then spectrophotometric absorbance of the resulting blue-colored supernatant measured at 570 nm using a computer-integrated microtiter plate reader.

**Results**

**Covalently bound dexamethasone content**

The predominant Phase I end product in PBS at pH 7.4 is a reactive dexamethasone carbodiimide phosphate ester intermediate complex (Figure 1). Addition of the reactive dexamethasone phosphate carbodiimide ester intermediate to IgG formulated in imidazole buffer at pH 6.0 preferentially produces a transient Phase II amine-reactive dexamethasone-phosphorylimidazolide intermediate (Figure 1). The aliphatic ε-monoamine of lysine residue side chains within the amino acid sequence of anti-IGF-1R monoclonal IgG then preferentially reacts with the Phase II dexamethasone-phosphorylimidazolide intermediate (Figure 1). Preferential reaction with the ε-monoamine of lysine amino acid residues is attributed to their significantly greater base characteristics compared to aromatic amines due to the electron sink effect imposed by organic ring structures. The covalent

![Figure 1](https://example.com/figure1.png)

**Notes:** Phase I, Phase II, and Phase III reaction schemes. Phase I: reaction of the dexamethasone C$_7$$_3$$_1$$_2$$_3$ monophosphate group with ε-ethyl-3-[3-dimethylaminopropyl] carbodiimide to transiently form a reactive dexamethasone-C$_7$$_3$$_1$$_2$$_3$ monophosphate carbodiimide ester intermediate complex; Phase II: a transient Phase I reactive intermediate is rapidly converted to a Phase II dexamethasone-C$_7$$_3$$_1$$_2$$_3$-phosphoroylimidazolide amine-reactive intermediate in the presence of imidazole. Phase III: the Phase II dexamethasone-C$_7$$_3$$_1$$_2$$_3$-phosphoroylimidazolide amine-reactive intermediate is reacted with the ε-amine of lysine residues within the amino acid sequence of anti-EGFR monoclonal immunoglobulin, resulting in the synthesis of a covalent dexamethasone-(C$_7$$_3$$_1$$_2$$_3$-phosphoramidate)-[anti-EGFR] immunopharmaceutical.

**Abbreviations:** EGFR, epidermal growth factor receptor type 1; IgG, immunoglobulin G.
phosphoramidate bond structure is highly stable at 4°C or in whole plasma or tissue culture media-like environments containing 5% plasma or 5% serum albumin in contrast to strictly aqueous buffer solutions devoid of biological proteins where at 37°C ~12% of total liberation rate occurs over a 100-hour period.48

Serial microfiltrations (MWCO =10 kDa) of dexamethasone-(C21-phosphoramidate)-[anti-EGFR] consistently yielded a Phase III covalent immunopharmaceutical end product that was devoid of any residual free noncovalently bound dexamethasone detectable by standardized analytical-HP-TLC (UV 254 nm) analysis of highly concentrated formulations (Figure 2).49–53 Results from these analyses were highly analogous to findings attained in previous investigations for covalent epirubicin59,51,52 and gemcitabine50,53 immunopharmaceutical that contained only ≤3%–4% of the total chemotherapeutic content as noncovalently bound chemotherapeutic, which cannot be removed by further serial applications of either microscale size-exclusion column chromatography or microfiltration methodologies.54

Molar incorporation index
The calculated dexamethasone: IgG molar-incorporation-index for covalent dexamethasone-(C21-phosphoramidate)-[anti-EGFR] was 6.95:1 utilizing the organic chemistry reaction scheme to form a covalent phosphoramidate bond at the C21-monophosphate group of dexamethasone. Microfiltration (MWCO =10 kDa) provided substantially greater yield levels for dexamethasone-(C21-phosphoramidate)-[anti-EGFR] than did the removal of residual unreacted chemotherapeutic/corticosteroid and reactive intermediates by microscale size-exclusion column chromatography.

Mass separation analysis for the detection of polymerization and fragmentation
Molecular weight profile analysis of covalent dexamethasone-(C21-phosphoramidate)-[anti-EGFR] immunopharmaceutical mass-separated by SDS-PAGE in combination with immunodetection analysis (Western blot) and chemiluminescent autoradiography recognized a single primary condensed band of 150 kDa between a molecular weight range of 5.0 kDa and 450 kDa (Figure 3). Profiles consistent with low molecular weight fragmentation (proteolytic/hydrolytic degradation) or high molecular weight IgG–IgG polymerization were not detected (Figure 3). The observed molecular weight of 150 kDa for dexamethasone-(C21-phosphoramidate)-[anti-EGFR] directly corresponds with the known molecular weight/mass of reference control anti-EGFR/anti-IGF-1R monoclonal IgG fractions (Figure 3). Analogous results have been reported for similar covalent immunochemotherapeutics.49–53,55,56

**Notes:** Lane 1: dexamethasone; Lane 2: dexamethasone (molar excess) and Phase II dexamethasone-phosphorylimidazolide amine-reactive intermediate; and Lane 3: Phase III covalent dexamethasone-(C21-phosphoramidate)-[anti-EGFR] immunopharmaceutical following serial microfiltration (MWCO =10 kDa). Standardized dexamethasone equivalent concentrations of dexamethasone-(C21-phosphoramidate)-[anti-EGFR], the dexamethasone-phosphorylimidazolide amine-reactive intermediate, and dexamethasone were applied to HP-TLC plates (silica gel, 250 μm thickness, UV 254 nm indicator) and developed utilizing a propanol/ethanol/H2O/glacial acetic acid (17:5:5:1, v/v) mobile phase. Identification of any residual dexamethasone or unreacted dexamethasone-phosphorylimidazolide in the Phase III covalent dexamethasone-(C21-phosphoramidate)-[anti-EGFR] immunopharmaceutical was subsequently determined by direct UV illumination. High concentrations of monoclonal IgG as a molecular component of covalent of the dexamethasone-(C21-phosphoramidate)-[anti-EGFR] immunopharmaceutical effectively quench UV detection of any chemotherapeutic moiety at the application origin.

**Abbreviations:** EGFR, epidermal growth factor receptor type 1; HP-TLC, high-performance thin layer chromatography.
Myosin 200 kDa →

β-Galactosidase 117 kDa →

Bovine serum albumin 75 kDa →

Carbonic anhydrase 43 kDa →

Soybean trypsin inhibitor 32 kDa →

Lysozyme 17 kDa →

Aprotinin 10 kDa →

Figure 3 Characterization of the molecular weight profile for the covalent immunopharmaceutical dexamethasone-(C_{21}-phosphoramide)-(anti-EGFR) relative to reference control anti-EGFR monoclonal immunoglobulin fractions and conventional molecular weight standards.

Notes: Lane 1: murine antihuman EGFR monoclonal immunoglobulin. Lane 2: dexamethasone-(C_{21}-phosphoramide)-(anti-EGFR). The covalent dexamethasone-C_{21}-phosphate immunopharmaceutical and monoclonal IgG fractions were size-separated by nonreducing SDS-PAGE followed by lateral transfer onto sheets of nitrocellulose membrane to facilitate detection with HRPO protein G conjugate. Subsequent analysis entailed incubation of membranes with a HRPO chemiluminescent substrate and the acquisition of autoradiography images.

Abbreviations: EGFR, epidermal growth factor receptor type 1; IgG, immunoglobulin G.

and 10.00 µg/mL corresponded with progressive elevations in the total amount of membrane-bound IgG (Figure 4). Collectively, results from cell-ELISA analyses validated the retained selective binding avidity of dexamethasone-(C_{21}-phosphoramide)-(anti-EGFR) for external membrane EGFR sites highly overexpressed on the exterior surface membrane of pulmonary adenocarcinoma (A549) monolayer populations (Figure 4). Detection of essentially no significant antineoplastic cytotoxic effect by anti-EGFR monoclonal immunoglobulin in an ex vivo cell culture environment over a relatively brief period of time very closely correlated with previously reported results.

Antineoplastic cytotoxic potency

Nearly identical levels of antineoplastic cytotoxic potency were detected individually for dexamethasone-(C_{21}-phosphoramide)-(anti-EGFR) and dexamethasone against pulmonary adenocarcinoma (A549) when challenged with dexamethasone equivalent concentrations at and between 10^{-9} M and 10^{-6} M over a 192-hour incubation period (Figure 5). Antineoplastic cytotoxicity of dexamethasone-(C_{21}-phosphoramide)-(anti-EGFR) increased rather dramatically at and between the standardized dexamethasone equivalent concentrations of 10^{-9} M, 10^{-8} M, and 10^{-7} M,
which corresponded with lethal cancer cell death values of 7.7%, 26.9%, and 64.9% (92.3%, 73.1%, and 35.1% residual survival), respectively (Figure 5). A much more gradual increase in antineoplastic cytotoxicity was detected at and between the standardized dexamethasone equivalent concentrations of 10⁻⁷ M, 10⁻⁶ M, and 10⁻⁵ M for dexamethasone-(C₂₁-phosphoramido)-[anti-EGFR], which were associated with the lethal cancer cell death values of 64.9%, 69.9%, and a maximum of 73.0% (35.1%, 30.1%, and 27.0% residual survival), respectively (Figure 5).

Discussion

Covariant biopharmaceuticals designed and synthesized to evoke antineoplastic cytotoxicity has primarily involved the implementation of anthracyclines, gemcitabine, methotrexate, mitomycin, vinca alkaloid analogs, bleomycin, chlorambucil, cyclophosphamide, paclitaxel (non-IgG), doxorubicin, calicheamicins, monomethyl auristatin E (MMAE). A relatively modest array of organic chemistry reaction schemes have been described for covalently binding dexamethasone and other steroid core pharmaceuticals to biologically relevant molecular platforms. Besides covalent compounding with other low molecular weight pharmaceuticals, corticosteroids have most commonly been covalently bound to a spectrum of high molecular weight platforms of natural origin, such as albumin, cardioplip, chondroitin sulfate (sulfated glycosaminoglycan), glucose-6-phosphate dehydrogenase, horseradish peroxidase, spermine, and cloned fusion proteins. Pharmacologicals with a steroid motif have additionally been covalently bound to artificial or semiartificial molecular platforms, such as amino-PEG (eg, α-methoxy-ω-amino-PEG), chitosan, dextran, N-(2-hydroxypropyl)methacrylamide, amine-modified polysaccharides, poly-L-glutamic acid (polypeptide configuration), 1-dodecylthio-2-decyloxypropyl-3-phosphatic acid, lipid nucleosides, N-(2-hydroxypropyl)methacrylamide polymer, benzodiazepine receptor ligands, 4-(N)-valeryl, 4-(N)-lauroyl, and 4-(N)-stearyl oxime, benzaldehyde derivatives (diagnostic positron-emitting radionucleotide), polyamidoamine dendrimer, and peptide hormone antagonists. The intent and purpose of covariantly bonding corticosteroids to biologically relevant molecular platforms has most frequently been for diagnostic-related applications and much less often for the development of advanced therapeutics. In rare instances where covalent corticosteroid biopharmaceutical therapeutics have been designed, synthesized, and evaluated for efficacy, it has most frequently been to determine their capacity to suppress cellular inflammatory responses utilizing molecular delivery platforms that include or are analogous to anti-EGFR or other steroid motif pharmaceuticals to target the presence of a carbodiimide following the initial formation of a corticosteroid and introduces a functionally reactive bisphosphoramido[anti-EGFR], receptor ligands (eg, epidermal growth factor [EGF] → EGF), or other high molecular weight biological proteins to date not been extensively described or has the design, the molecular structure, or organic chemistry reaction regimes been reported that describe the synthesis of covariant corticosteroid biopharmaceuticals that exert properties of selectively targeted antineoplastic cytotoxic potency relevant to conditions of leukemia or lymphoma.

Precarboxylated corticosteroid/steroid intermediate analogs

Precarboxylation of corticosteroids and steroid core pharmaceuticals is an initial requirement for some organic chemistry reactions which has most frequently been to determine their synthetic utility by covalently bonding them covalently to biologically relevant molecular platforms. Corticosteroid/steroid precarboxylation can be achieved utilizing different organic chemistry reaction schemes. Hydrazine acetic acid ethyl ester and heating to 120°C produce a hydrazino acetic acid analog of a corticosteroid/steroid and introduces a carboxyl group and an acid-cleavable hydrazino group at the C₂₁ position. Precarboxylation of corticosteroids/steroids through the introduction of (O-carboxymethyl)oxime is achieved by first converting a hydrogen (–CH₂OH) group into an aldehyde (–CHO) through the application of chromium (VI) oxide, anhydrous magnesium sulfate, pyridine, dichloromethane, and ether. The corticosteroid/steroid aldehyde is then combined with O-(carboxymethyl)hydroxylamine hemihydrichloride and is further processed utilizing toluene, ether, ethyl acetate, methanol, NaHCO₃, and H₂SO₄ to yield an O-(carboxymethyl)oxime analog. Corticosteroids/steroids in combination with a dicarboxylic organic acid-like glutarate can be converted to a carboxyl ester analog at an available hydroxyl group (eg, C₂₁-OH) in the presence of a carbodiimide following the initial formation of a reactive glutarate O-aclylsourea ester intermediate. Some corticosteroid/steroid hemisuccinate analogs (eg, C₂₁ position) are commercially available or they can be synthesized utilizing succinic anhydride reagent in combination with sodium sulfate, pyridine, chloroform, acetone, and benzene/hexane. Similarly, covariant corticosteroid/steroid (O-carboxymethyl)oxime analogs can be synthesized “in-house” utilizing a wide spectrum of reagents including (O-carboxymethyl)hydroxylamine in combination with sodium sulfate, pyridine, methanol, and benzene/hexane.
with diazomethane, N-nitroso-N-methylurea, aluminum isoproxide, ethyl acetate, ether, acetone, benzene, KOH, and HCl reagents. Carboxylation of corticosteroids/steroids through the introduction of glutarate, hemisuccinate, or \(-\text{(O-carboxymethyl)oxime}\) can potentially occur at hydroxyl groups located at the C\(_3\), C\(_6\), C\(_{11}\), C\(_{17}\), or C\(_{21}\) positions within the chemical structure of steroid core pharmaceuticals. Alternatively, some but not all corticosteroids/steroids can be obtained commercially as hemisuccinate\(^{24,26,109}\) or \(-\text{(O-carboxymethyl)oxime}\) analogs.

**Preaminated corticosteroid/steroid intermediate analogs**

Corticosteroid/steroid monoamine analogs can be produced utilizing N-trityl-glycine and a carbodiimide resulting in the production of a trityl-glycine-steroid intermediate that is then converted by AcOH to a glycycl steroid (eg, glycycl-prednisolone).\(^{29}\) In a second reaction, the monoamine group of the glycycl steroid is transformed into a covalent amide bond structure at a carboxyl group associated with a biologically relevant molecular platform (eg, chondroitin sulfate) in the presence of a carbodiimide and \(N\)-hydroxysuccinimide (NHS).\(^{29}\) Given this general synthesis strategy, corticosteroids/steroids initially can be converted to either a monoamine or a monocarboxyl analog that is then covalently bound to a biologically relevant molecular platform at an available primary carboxyl or primary amine group, respectively.

**Covalent bonding of carboxylated corticosteroid/steroid analogs independent of carbodiimide**

A limited number of carbodiimide-independent organic chemistry reaction schemes have been developed for covalent bonding of carboxylated corticosteroids/steroids to biologically relevant molecular platforms. Carboxylated corticosteroids/steroids in the form of either hemisuccinate analogs or \(-\text{(O-carboxymethyl)oxime}\) analogs can be covalently bound to proteins through a mixed anhydride reaction when performed in combination with acetic anhydride, 2-methyl-6-nitrobenzoic anhydride, tri-n-butylamine, isobutyrylcholorcarbonate, gamma amino-\(n\)-butyric acid, dioxane, acetone, NaOH, and HCl reagents.\(^{23–25,31,105,106,116,127,128}\) During mixed anhydride reactions of the Dalziel Hammick type (\(R\text{CO}_2\text{H} + H_2\text{C}=\text{C}=\text{O} \rightarrow R\text{CO}_2\text{C}(_\text{O})\text{CH}_3\)), corticosteroids become covalently bound to a second biologically relevant molecular platform at an available primary carboxyl group. A disadvantage of some mixed anhydride reactions is the associated increased risk of generating high molecular weight end products when the organic chemistry scheme is allowed to progress, resulting in the occurrence of polymer-forming side reactions.\(^{25}\)

**Carbodiimide-dependent covalent bonding of carboxylated corticosteroid/steroid analogs**

Many, if not majority, of the methods for covalent bonding of corticosteroids and other pharmaceuticals with a steroid core to a biologically relevant molecular platform use a carbodiimide reagent that forms a covalent amide bond structure between primary carboxyl and primary amine groups. A characteristic of carbodiimide reagents is their formation of a transient \(O\)-acylisourea intermediate at primary carboxyl groups that can be either immediately reacted with a primary amine group or reacted with NHS to create a more stable and amine-reactive corticosteroid/steroid NHS ester intermediate.\(^{24}\) Carboxylated corticosteroids/steroids, such as hemisuccinate,\(^{24,109,125}\) glutarate,\(^{28}\) and \(-\text{(O-carboxymethyl)oxime}\) analogs, in anhydrous DMSO or dimethylformamide (DMF) are converted by carbodiimides to a transient \(O\)-acylisourea intermediate.\(^{24,26,109}\) Some reaction schemes simultaneously utilize 1-hydroxybenzotriazole, 1-hydroxy-7-azabenzotriazole, or similar reagents to suppress racemization.\(^{125}\) Electrophilic properties of the monocarboxyl group of modified corticosteroid/steroid analogs increase following their reaction with carbodiimide reagents. The negatively charged carboxyl oxygen has nucleophile characteristics and forms a covalent bond with the central carbon atom of the functional group (R–N=C=N–R) of carbodiimides. Carboxylated corticosteroid/steroid \(O\)-acylisourea ester intermediates ultimately can be reacted with several different chemical groups associated with a biologically relevant molecular platform: 1) primary amine groups resulting in the formation of a covalent amide bond structure;\(^{125}\) 2) hydroxyl groups resulting in the formation of a covalent ester bond structure;\(^{28}\) and alternatively with 3) NHS resulting in the production of a relatively stable amine-reactive corticosteroid/steroid NHS ester intermediate in the presence of dioxane and DMF.\(^{24,26,109}\) When \(O\)-acylisourea ester\(^{125}\) and NHS ester\(^{24,27}\) intermediates of corticosteroids/steroids are reacted with the \(\varepsilon\)-monoamine of lysine amino acid residues within the sequence of biologically relevant peptides, polypeptides, and proteins, they form a stable covalent amide bond structures. Such synthesis regimens may require performing this phase of the reaction scheme in anhydrous dioxane, DMSO, or DMF.

---

**References:**

1. Dur-...
in the presence of 1-hydroxybenzotriazole (suppresses racemization).\textsuperscript{34,125}

**Preliminary synthesis of the amine-reactive dexamethasone-(C\textsubscript{21}-phosphorylimidazole) intermediate**

The molecular design of dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-IGF-1R] and organic chemistry reactions embedded within a multiphase synthesis regime represents a notable departure from previously described methodologies for covalent immunochemotherapeutics.\textsuperscript{24,26,28,109,125} The organic chemistry reactions used in the multiphase synthesis scheme for dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-EGFR] involved the initial generation of a transient Phase I dexamethasone-C\textsubscript{21}-phosphate ester-carbodiimide reactive intermediate that rapidly transforms in the presence of imidazole into a more stable Phase II dexamethasone amine-reactive phosphorylimidazole intermediate (Figure 1). Dexamethasone-C\textsubscript{21}-phosphate was formulated at a relatively large molar excess to the carbodiimide reagent in order to 1) maximize the yield of the Phase II amine-reactive dexamethasone-C\textsubscript{21}-phosphate intermediate, 2) accelerate the rate of the organic chemistry reaction, 3) promote the maximal depletion of the carbodiimide reagent (also unstable for prolonged incubation periods in aqueous-based buffer systems), and 4) minimize the risk of high molecular weight IgG–IgG polymerization.

**Covalent bonding of an amine-reactive dexamethasone-(C\textsubscript{21}-phosphorylimidazole) intermediate to immunoglobulin**

In Phase III of the organic chemistry synthesis scheme, the Phase II dexamethasone-(C\textsubscript{21}-phosphorylimidazole) was ultimately reacted with the ε-monoamine group of lysine residues within the amino acid sequence of anti-EGFR monoclonal IgG, resulting in the formation of a covalent phosphoramide bond structure at the dexamethasone C\textsubscript{21} position (Figure 1). A relatively limited number of organic chemistry reactions can be utilized to covalently bond chemotherapeutic moieties to biologically relevant molecular platforms utilizing conditions and reagents that do not detrimentally modify their function and integrity. A covalent amide bond structure is most commonly formed at the ε-monoamine group of lysine residues within the amino acid sequence of most common biologically relevant molecular platforms that are peptide subunits or proteins. Alternatively, either IgG and other glycoproteins can also be prethiolated (introduction of reduced sulfhydroyl R-SH groups) at ε-monoamine of lysine amino acid residues or covalent bond structures can be formed at aldehyde groups within the carbohydrate component created by limited oxidation.

**Multiphase organic chemistry synthesis scheme qualities and advantages**

In addition to the classical variables of temperature, concentrations, and reaction time duration that can be modified to enhance efficiency and yield of organic chemistry reactions, there are several other parameters that likely contributed to achieving a dexamethasone:IgG molar-incorporation-index of 6.95:1 for dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-EGFR], including 1) lack of a prethiolation requirement for anti-IGF-1R immunoglobulin; 2) potentially greater relative chemical reactivity of carbodiimide analogs compared to other previously applied covalent bond forming reagents; 3) enhanced preferential phosphate reactivity of the carbodiimide reagent in the presence of imidazole; 4) formation of a covalent bond at the single available monophosphate group located at the C\textsubscript{21} position in contrast to a phosphate (Ar-PO\textsubscript{3}\textsuperscript{2−}), carboxyl (Ar-CO\textsubscript{2}\textsuperscript{−}), amine (Ar-NH\textsuperscript{+}), or sulfhydryl (Ar-SH) chemical group located directly on any one of the four aromatic ring structures; 5) restricting the initial chemical reaction of the carbodiimide reagent with only the dexamethasone-C\textsubscript{21}-monophosphate in a manner that enhanced yield and minimized generation of side reaction end products (IgG-based determination); 6) formulation of dexamethasone-C\textsubscript{21}-monophosphate group in molar excess to the carbodiimide in order to promote maximal depletion of the covalent bond-forming reagent; 7) selective amine reactivity of the Phase II dexamethasone-(C\textsubscript{21}-phosphorylimidazole) intermediate; and 8) presence of only a single phosphate group within the chemical composition of dexamethasone-C\textsubscript{21}-monophosphate.

Presence of the single phosphate group at the C\textsubscript{21} instead of the C\textsubscript{11} or C\textsubscript{17} position of dexamethasone decreases both the influence of steric-hindrance phenomenon at the C\textsubscript{21}-monophosphate of dexamethasone-C\textsubscript{21}-monophosphate during initial chemical reactions with a carbodiimide and the unique influences from aromatic electron orbital properties associated with any one of the four planar ring structures which often modifies the chemical characteristics of phosphate (Ar-PO\textsubscript{3}\textsuperscript{2−}), carboxyl (Ar-CO\textsubscript{2}\textsuperscript{−}), and amine (Ar-NH\textsuperscript{+}) groups. Complementing the effectiveness of the organic chemistry reactions, the final yield of dexamethasone-(C\textsubscript{21}-phosphoramidate)-[anti-EGFR] was substantially improved by implementing both a multiphase organic chemistry reaction scheme (in preference to a single-phase “co-mingled”
reagent regimen) in concert with the removal of residual dexamethasone-$C_{21}$-monophosphate and unreacted reagents from dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] by serial microfiltration (MWCO $=10$ kDa) in preference to the application of microscale column chromatography for the separation and purification of the final Phase III covalent immunopharmaceutical end product. Logistical attributes of the multiphase organic chemistry reaction scheme utilized for the synthesis of dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] consisted of 1) comparatively brief incubation time periods for organic chemistry reactions utilized in the multiphase synthesis regimen; 2) relatively efficient execution of organic chemistry reaction regimens; 3) option of producing an amine-reactive Phase II dexamethasone intermediate that is stable enough for short- to long-term preservation/storage; 4) flexibility of substituting other pharmaceutical agents in the organic chemistry reaction scheme in place of dexamethasone; 5) flexibility of substituting other biologically relevant molecular platforms for anti-EGFR monoclonal IgG; 6) option of modifying organic chemistry reaction scheme within the multiphase synthesis regimen in a manner that affords higher or lower molar incorporation ratios; 7) moderate-to-high levels of laboratory technical convenience; and 8) a low degree of dependence on the utilization of advanced forms of laboratory instrumentation.

**Dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] selectively targeted antineoplastic cytotoxic potency**

The selective antineoplastic cytotoxic potency of dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] against pulmonary adenocarcinoma (A549) was nearly identical to dexamethasone when formulated at and between the standardized dexamethasone equivalent concentrations of $10^{-8}$ M and $10^{-6}$ M (Figure 4). Acknowledgment of both the molecular weight of dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] and the known mechanism of action for dexamethasone collectively serve to validate the concept that covalent the dexamethasone immunopharmaceutical was effectively internalized by the active transport mechanism of IgG-induced receptor-mediated endocytosis. A complementary quality of dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] is that the insertion or addition of no “foreign” chemical groups into dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] during synthetic formation of the $C_{21}$-phosphoramide bond structure which decreases the risk of inducing host humoral immune responses. Other innate attributes include retained molecular weight and more importantly retained biological activity of the anti-EGFR component within dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] in the form of binding avidity for EGFR overexpressed on the external surface membrane of pulmonary adenocarcinoma (A549).

Ultimately, the total combined selective targeted antineoplastic cytotoxicity afforded by dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] is logically presumed to be substantially enhanced in vivo by IgG–antigen complex stimulation of endogenous host immune responses that are difficult to simultaneously access ex vivo utilizing a tissue culture-based model for neoplastic disease.

**Attributes of covalent dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] immunopharmaceutical**

The molecular design of dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] provides several distinct qualities pertaining to chemical composition and molecular structure. Importantly, the multiphase organic chemistry reaction scheme utilized to synthesize dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] generated a Phase III end product with a 6.95:1 dexamethasone:IgG molar-incorporation-index. A dexamethasone:IgG molar-incorporation-index of 6.95:1 for dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] was modestly greater than values obtained in previous investigations using other covalent bond-forming agents for the synthesis of 1) gemcitabine-(C$_6$-carbamate)-[anti-HER2/neu] (Gem:IgG $=1.1:1$), 2) gemcitabine-(C$_2$-amide)-[anti-HER2/neu] (Gem:IgG $=2.78:1$), 3) epirubicin-(C$_{13}$-amide)-[anti-HER2/neu] (Epi:IgG $=0.275:1$), 4) epirubicin-(C$_2$-amide)-[anti-EGFR] (Epi:IgG $=0.407:1$), and 5) epirubicin-(C$_{13}$-imino)-[anti-HER2/neu] (Epi: IgG $=0.400:1$). In the chemical configuration of dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR], the corticosteroid moiety is covalently bound to anti-EGFR through a $C_{21}$-phosphoramide bond structure that at least in theory provides potentially higher levels of bioavailability for the dexamethasone moiety after it enters the acidic microenvironment of the phagolysosome following selective targeted delivery and internalization by active transport mechanisms of IgG-induced receptor-mediated endocytosis. A complementary quality of dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] is the insertion or addition of no “foreign” chemical groups into dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] during synthetic formation of the $C_{21}$-phosphoramide bond structure which decreases the risk of inducing host humoral immune responses. Other innate attributes include retained molecular weight and more importantly retained biological activity of the anti-EGFR component within dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] in the form of binding avidity for EGFR overexpressed on the external surface membrane of pulmonary adenocarcinoma (A549).

The molecular design and organic chemistry reactions implemented for the synthesis of dexamethasone-($C_{21}$-phosphoramide)-[anti-EGFR] used anti-EGFR monoclonal
IgG as a molecular delivery platform because of its selective binding avidity for epidermal growth factor membrane receptors (EGFR, ErbB-1, and HER1). Motivation for utilizing EGFR as a site to facilitate the selective targeted delivery of a covalent dexamethasone-(C$_{21}$-phosphoramide)-[IgG] immunopharmaceutical was to a large part dependent on the utilization of pulmonary adenocarcinoma (A549) as an ex vivo neoplastic disease model, which is known to uniquely overexpress both EGFR and IGF-1R trophic membrane receptors. A wide spectrum of adenocarcinomas and carcinomas uniquely overexpress each of these two trophic receptors in addition to HER2/neu on their exterior surface membrane. EGFR (ErbB-1 and HER1) is a 170 kDa glycoprotein within the ErbB epidermal growth factor family of receptors. The nonprotein component of EGFR is located on the external surface of cell membranes and consists of an N-linked glycan with a GlcNAc terminus. The ligands, such as EGF and transforming growth factor-α, activate EGFR, and upon stimulation, it is transformed from an EGFR monomer complex to an activated homodimer. The transformation results in marked increases in intrinsic intracellular protein tyrosine kinase activity and autophosphorylation of tyrosine residues. Such changes initiate downstream activation and signaling of several proteins that in turn induce the mitogen-activated protein kinases, Akt, and JNK signal transduction cascades that ultimately lead to DNA synthesis and increased cellular proliferation. Mutations characterized by EGFR overexpression promote persistent stimulation and patterns of uncontrolled cellular division. Immunotherapeutics in the form of monoclonal antibody inhibitors with binding avidity for the EGFR oncoprotein receptor block the extracellular ligand-binding domain, thereby blocking signal transduction. Other monoclonal antibody inhibitors have been developed that inhibit activity of the cytoplasmic tyrosine kinase segment of EGFR resulting in the receptor not being able to selfactivate.

Uniquely or highly overexpressed trophic membrane receptors (eg, EGFR, IGF-1R, HER2/neu, and vascular endothelial growth factor receptor) associated with many forms of adenocarcinoma and carcinoma, in addition to certain cell differentiating antigens (eg, CD19, CD20, CD22, and CD30) found on leukemia and lymphoma cell types, are each capable of facilitating both the selective targeted delivery and receptor-mediated endocytosis of a wide spectrum of covalent immunopharmaceuticals analogous in the form and function to dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR]. Monoclonal IgG with binding avidity for endogenous trophic membrane receptors have the potential to exert other additional biological properties that are independent of the activity associated with pharmaceutical moieties when incorporated as a component of covalent immunopharmaceuticals, such as dexamethasone-(C$_{21}$-phosphoramide)-[anti-EGFR]. Monoclonal IgG with binding avidity for EGFR, HER2/neu, IGF-1R, VEGFR, or other endogenous trophic membrane receptors can therefore 1) competitively inhibit binding and stimulation by endogenous trophic ligands at shared epitopes (eg, EGF $\sim$ IgG-EGFR), 2) transiently reduce surface membrane expression densities as a desirable consequence of induced receptor-mediated endocytosis, and 3) reduce the biochemical function of certain receptor subtypes (eg, anti-HER2/neu $\rightarrow$ HER2/neu tyrosine kinase activity). Monoclonal IgG with binding avidity for trophic receptors, such as EGFR, IGF-1R, and HER2/neu that are uniquely or highly overexpressed on the external surface membrane of neoplastic cell types, can therefore suppress the proliferation rate and viability of various neoplastic cell types, affecting the breast, prostate, lung, and some sarcomas. Competitive inhibition of overexpressed endogenous trophic receptors, such as EGFR, in neoplastic cell types can also reduce metastatic transformation, mobility, and metastatic potential. Inhibition of overexpressed endogenous trophic membrane receptor, therefore, affords an approach to suppressing neoplastic conditions refractory (resistant) to conventional low molecular weight chemotherapeutics while at the same time avoiding the risk of many serious sequellae.

In addition to facilitating selective pharmaceutical targeted delivery and blocking endogenous ligand binding at trophic receptor sites, the covalent bonding of dexamethasone, classical low molecular weight chemotherapeutics, or other types of anticancer agents specifically to monoclonal IgG with binding avidity for uniquely or highly overexpressed endogenous trophic receptors or cell differentiation proteins can serve an effective means for recruiting and selectively “targeting” multiple host immune responses. Formation of membrane IgG:Ag complexes on the external surface of neoplastic cell types can evoke the selectively “targeted” endogenous host immune responses that collectively involve the activation of 1) ADCC, 2) CMC, and 3) opsonization/phagocytosis. Secondary antineoplastic properties from the activation of antibody-dependent cell-mediated cytoxicity in general are more efficient and have greater effectiveness when the monoclonal immunoglobulin utilized is either the IgG$_1$ isotype or the IgG$_2$ isotype. Monoclonal IgG fractions with binding avidity for trophic membrane receptors that have most extensively been utilized in clinical oncology for the therapeutic management of adenocarcinomas and carcinomas affecting the breast, prostate, intestine, and lung.
include anti-HER2/neu (trastuzumab and pertuzumab),\textsuperscript{130–134} anti-EGFR (cetuximab),\textsuperscript{135–138} combined anti-HER2/neu and anti-EGFR (panitumumab),\textsuperscript{137–140} and anti-IGF-1R (igitumumab and dalotuzumab).\textsuperscript{141–144} In contrast to many nonhematopoietic neoplastic conditions, leukemia and lymphoma either uniquely or highly overexpress sites on their external surface membrane that do not function as classical endogenous trophic receptor complexes and include the cell differentiation antigens, such as CD20, CD22, CD30 (TNFRSF8), CD33 (SIGLEC: sialic acid-binding lectin), and CD54. Each of these cell differentiation antigens has served as the basis for the development of therapeutic monoclonal immunoglobulins, such as anti-CD20 (ibritumomab, ofatumumab, rituximab, trubion, and veltuzumab) for B-cell non-Hodgkin’s lymphoma, resistant CLL, other lymphomas, leukemia, transplant rejection, and autoimmune disease; anti-CD22 (inotuzumab) for non-Hodgkin’s lymphoma; anti-CD33 (gemtuzumab) for acute myeloid leukemia (AML); and anti-CD52 (alemtuzumab) for CLL, cutaneous T-cell lymphoma, and T-cell lymphoma. Nonhematopoietic neoplastic cells can similarly uniquely overexpress cell differentiation antigens including CD44 (bivatuzumab) relevant to breast cancer and CD66e (carcinoembryonic antigen-related cell adhesion molecule: labetuzumab) associated with intestinal carcinoma. Most of the cell differentiation antigens overexpressed by leukemia and lymphoma cell types do not function as endogenous receptors and are not known to bind endogenous hormone-like ligands so monoclonal immunoglobulins with binding avidity at these sites do not exert extensive degrees of neoplastic cell inhibition through the same processes as those documented for anti-EGFR, anti-IGF-1R, anti-HER2/neu, or anti-VEGFR in adenocarcinomas, carcinomas, or other nonhematopoietic neoplastic cell types. Alternatively, the antiangiopietic properties of anti-CD20, anti-CD22, anti-CD33, and anti-CD54 attained in vivo against populations of leukemia and lymphoma cell types are instead highly dependent upon if not largely restricted to the activation of endogenous immune responses.\textsuperscript{13–18,20,38,145,146} Majority, if not all, of the in vivo antineoplastic cytotoxic properties of anti-CD20, anti-CD33, and anti-CD54 is therefore predominate attained through their ability to induce multiple endogenous host immune responses.\textsuperscript{147–152}

Despite the inhibitory characteristics of anti-HER2/neu, anti-EGFR, anti-IGF-1R, and similar monoclonal IgG-based modalities on the function of membrane trophic receptors, they frequently only suppress the in vivo proliferative growth and vitality of cancer cells but they are almost invariably incapable independently of evoking a degree of cytotoxic activity sufficient enough to successfully resolve most aggressive or advanced forms of neoplastic disease.\textsuperscript{130,131,153–167} Inability of most immunoglobulins with binding avidity for trophic membrane receptors to exert significant cytotoxic efficacy in vivo coincides with the detection of increases in cell-cycle G\textsubscript{1} arrest, cancer cell transformation into states of apoptosis resistance,\textsuperscript{159} and preferential selection for resistant subpopulations.\textsuperscript{130,131} In addition, this scenario can be further complicated by frequent reversal of tumor growth inhibition\textsuperscript{130} and relapse of trophic receptor overexpression\textsuperscript{173} upon cessation and withdrawal. Greater levels of antineoplastic cytotoxicity are attainable when antitrophic receptor IgG is utilized in dual combination with conventional chemotherapy or other cancer treatment modalities.\textsuperscript{168–170} Development of resistance has also been detected for monoclonal IgG with binding avidity for cell differentiation proteins, such as anti-CD20 (veltuzumab and ofatumumab) and anti-CD52 (alemtuzumab). Mechanisms of resistance associated with monoclonal IgG fractions with binding avidity for these and other membrane-associated cell differentiation antigens are attributed to 1) accelerated rates of receptor-mediated endocytosis prior to ADCC/CMC/opsonization,\textsuperscript{13,19} 2) monocyte/macrophage CD20/CD52 shaving or trogocytosis,\textsuperscript{20} and 3) immune evasion as a consequence of immunosuppressive mediators liberated from cancer cell populations.\textsuperscript{21,22} Interestingly, ofatumumab has been approved for B-CLL resistant to alemtuzumab and fludarabine.

In an ex vivo tissue culture environment, most of the therapeutic monoclonal IgGs with binding avidity for overexpressed trophic membrane receptors evoke very limited or a total lack of any measurable selectively targeted antineoplastic cytotoxicity or detectable inhibition of vitality and viability.\textsuperscript{49,56,80,171–177} Multiple variables contribute to this observation, but some of the most important and relevant in this regard include the 1) comparatively low concentration of endogenous trophic ligands present in conventional tissue culture media (eg, 5\%–10\% bovine serum), 2) relatively brief incubation periods used to access efficacy and potency (eg, 3–8 days), and 3) absence of significant activation of or influence from any of the three endogenous host immune responses. Monoclonal IgG, including anti-HER2/neu, anti-EGFR, and anti-IGF-1R, with binding avidity for trophic membrane receptors in vivo produces detectable decline in neoplastic cell proliferation and vitality. However, monoclonal IgG bound to antigenic sites on the external surface membrane of neoplastic cells can also induce selectively targeted host immune responses that can produce a significant cytotoxic effect. Most notable in this regard are
ADCC, CMC, and opsonization/phagocytosis that serve as the immunology mechanisms primarily responsible for anti-CD20 and anti-CD52 efficacy and potency against leukemia neoplastic disease states.

Despite limited anticancer cytotoxicity and a general inability in vivo to independently resolve many neoplastic disease states, monoclonal IgG with binding avidity for unique or highly overexpressed "sites" on the external surface membrane of many neoplastic cell types makes them nearly ideally suited for selectively targeting delivery of therapeutic or diagnostic moieties. The mechanism of action for diagnostic radioimmunopharmaceutical agents, or anticancer therapeutic agents that exert biological activity through physical and functional disruptions of cancer cell membrane integrity, does not require direct entry into cytosol or nuclear environments (eg, [211Bi or 212At or 224Ra]-anti-TAG-72 for colon carcinoma). In contrast, passive or active transmembrane transport is particularly relevant and essentially a requirement when pharmaceutical moieties are utilized in the synthesis of covalent immunopharmaceuticals that have a mechanism of action that is entirely dependent on their entry into cytosol or nuclear environments. Because of this consideration, a second critically important biological function of surface membrane sites that can make them invaluable as "targets" for the facilitation of selective delivery of pharmaceutical moieties is an ability to be internalized intracellularly by mechanisms of receptor-mediated endocytosis following and in response to selective binding of immunoglobulin or endogenous ligands. Intracellular internalization of dexamethasone-(C21-phosphoramidate)-[anti-EGFR] by the transmembrane active transport mechanism of receptor-mediated endocytosis provides the advantage of minimizing or avoiding the simple "coating" of the external surface membranes of neoplastic cell populations. Highly desirable sites on the external surface membrane of neoplastic cell types for facilitating selectively targeted pharmaceutical delivery include the endogenous trophic membrane receptors, such as EGFR, IGF-1R, HER2/neu, and VEGFR, in addition cell differentiating antigens, such as CD19, CD20, CD22, and CD30, because they are both uniquely and highly overexpressed and are internalized by processes of induced receptor-mediated endocytosis. The functional implications of both unique and high overexpression in addition to an ability to undergo internalization induced by mechanisms of receptor-mediated endocytosis collectively allows such membrane sites to directly influence the efficacy and potency of covalent immunopharmaceuticals and analogous biopharmaceutical agents.

The selective targeted binding of dexamethasone-(C21-phosphoramidate)-[anti-EGFR] to uniquely or highly overexpressed sites on the external surface membrane of neoplastic cell types that have the capacity to facilitate the active transmembrane transport of the covalent immunopharmaceutical by induced receptor-mediated endocytosis contributes to attaining several critically important attributes that directly influence efficacy. The IgG component of covalent immunopharmaceuticals that possesses selective binding avidity for uniquely or highly overexpressed endogenous receptors therefore can promote 1) selective targeted pharmaceutical moiety delivery, 2) continual deposition of a pharmaceutical moiety on external surface membranes of cancer cells as a function of trophic receptor expression/reexpression, 3) persistent high levels of transmembrane active pharmaceutical transport by mechanisms of receptor-mediated endocytosis, and 4) progressive cytosol pharmaceutical accumulation resulting in concentrations that can exceed those possible by simple passive diffusion (eg, postintravenous injection of classical low molecular weight chemotherapeutics at therapeutically relevant dosages). Monoclonal antibody with binding avidity for CD74 (myeloma), CEA (colon carcinoma), and CD33 (promyelocytic leukemia and myeloid leukemia) is known to be internalized by mechanism analogous to receptor-mediated endocytosis detected for EGFR- and HER2/neu-positive adenocarcinoma and carcinoma cell populations. Although specific data for IGF-1R-mediated endocytosis are somewhat limited for pulmonary adenocarcinoma (A549), other neoplastic cell types, such as Lewis Lung carcinoma (H-59: highly metastatic subculture with hepatic propensity) and mammary adenocarcinoma (MCF-7), are known to actively internalize membrane IGF-1Rs by mechanisms of receptor-mediated endocytosis at a rate of 4.5 × 10^4 molecules of anti-CD74 monoclonal antibody per day. Related investigations have demonstrated that metastatic multiple myeloma internalizes and metabolizes ~8 × 10^4 molecules of anti-CD74 monoclonal antibody per day. Given this perspective, the three most critical numerical variables related to cancer cell biology that determines the antineoplastic cytotoxic potency of covalent immunopharmaceuticals, such as dexamethasone-(C21-phosphoramidate)-[anti-EGFR], gemcitabine-(C2-carbamate)-[anti-HER2/neu], gemcitabine-(C2-amide)-[anti-HER2/neu], epirubicin-(C2-amide)-[anti-HER2/neu], epirubicin-(C2-imino)-[anti-HER2/neu] are the 1) external surface membrane expression density of endogenous trophic receptor targets relative to normal healthy cells residing in tissues and organ systems,
2) rate of internalization by mechanisms of receptor-mediated endocytosis, and 3) rate that receptors on the external surface membrane are subsequently replenished following internalization by receptor-mediated endocytosis.

The capacity of dexamethasone-(C$_{21}$-phosphoramidate)–[anti-EGFR] to selectively target dexamethasone delivery at EGFR membrane receptor sites and subsequently promote IgG-induced receptor-mediated endocytosis functionally represents an active transport mechanism activated in neoplastic cell populations that can promote and facilitate substantial intracellular accumulation of pharmaceutical moieties. A direct outcome of receptor-mediated endocytosis of membrane-bound covalent immunocorticosteroid can be an increase in the intracellular cytosol concentrations of pharmaceutical moieties that are 8.5-fold$^{12}$ to $>100$-fold$^{33,34}$ greater than those attainable by simple passive diffusion of conventional low molecular weight pharmaceuticals from the extracellular fluid compartment following intravenous injection at clinically relevant dosages. Active transport of dexamethasone or other pharmaceutical agents across intact cancer cell membranes by mechanisms of IgG- or ligand-induced receptor-mediated endocytosis following selective targeted delivery at endogenous membrane receptors can therefore serve as a strategy capable of 1) maximizing therapeutic efficacy and potency, 2) accelerating cytotoxic resolution of neoplastic cell populations, 3) reducing the influence of chemotherapeutic resistance, $^{176-181}$ and 4) decreasing the time frame during which acquired chemotherapeutic resistance can potentially develop. The latter consideration is particularly relevant to many conditions of leukemia and lymphoma that are capable of developing resistance to corticosteroid therapy over a relatively brief time period.

Therapeutic properties potentially afforded by monoclonal immunoglobulin with binding avidity for sites on the external surface membrane of neoplastic cell types are frequently complemented by the efficacy of chemotherapeutic agents. Antineoplastic properties of anti-HER2/neu are additively or synergistically increased by cyclophosphamide, $^{169,182}$ doxorubicin, $^{169,182}$ etoposide, $^{32}$ methotrexate, $^{32}$ paclitaxel, $^{169,182}$ or vinblastine. $^{182}$ Similar to anti-HER2/neu, $^{169,182-186}$ the antineoplastic properties of other monoclonal immunoglobulin inhibitors of trophic membrane receptors, including anti-EGFR, $^{187-189}$ anti-IGF-1R, $^{190,191}$ and anti-VEGFR, $^{168,192,193}$ are also additively and synergistically complemented by conventional chemotherapeutic agents. In conditions of leukemia and lymphoma, monoclonal anti-CD22 immunoglobulin has been applied in the development of both inotuzumab ozogamicin (calicheamicin: DNA strand scission) and moxetumomab pasudotox (CAT-8015: active Pseudomonas-origin exotoxin). Each of these anti-CD22-based biotherapeutics has demonstrated efficacy against non-Hodgkin’s lymphoma or hairy cell leukemia, respectively. Monoclonal anti-CD30 covalently bound to highly toxic MMAE (brentuximab vedotin) similarly possesses antineoplastic efficacy that is associated with the MMAE moiety, which has a mechanism of action involving inhibition of tubulin polymerization and has been found to be effective for therapeutic management of Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma. AML has been therapeutically managed with variable degrees of effectiveness utilizing the monoclonal anti-CD33-based immunochemotherapeutics, gemtuzumab ozogamicin (2000–2010 United States Federal Drug Administration withdrawal), and SGN-CD33, which contain pyrrolobenzodiazepine (promotes intrastand DNA cross-linking) as a chemotherapeutic moiety. In anti-CD33 therapeutic monoclonal IgGs or anti-CD33-based covalent immunochemotherapeutics, some of the anticancer properties attained are associated with the tyrosine-based inhibitory motif located intracellularly and its relationship or influence on inhibiting the cellular activity. Monoclonal anti-CD56 immunoglobulin has been covalently bound to a mertansine (maytansinoid analog) chemotherapeutic moiety to form lorvotuzumab mertansine, which has demonstrated efficacy against CD56-positive multiple myeloma.

Many attributes of antitrophic receptor IgGs (eg, anti-EGFR) in dual combination with the biological activity of pharmaceutical moieties (eg, dexamethasone) provide a strategy for establishing the molecular design and organic chemistry synthesis of covalent immunopharmaceuticals, such as dexamethasone-(C$_{21}$-phosphoramidate)–[anti-EGFR], which exerts synergistic or additive levels of therapeutic potency, which is attained collectively through multiple mechanisms of action. Additionally, molecular platforms, such as IgG and endogenous ligands, impart other properties and beneficial attributes that substantially complement their potential to facilitate selective targeted pharmaceutical delivery by processes that are distinctly different from their innate properties of selective binding avidity or an ability to induce receptor-mediated endocytosis. The molecular weight and overall size of IgG and many endogenous trophic receptor ligands (eg, IgG molecular weight [MW] =150 kDa and EGF MW =6.05 kDa) are much greater than the size of the vast majority of conventional low molecular weight pharmaceuticals and chemotherapeutic agents (dexamethasone MW =392.461, fludarabine MW =365.212, and gemcitabine MW =263.198). Due to this innate biological characteristic,
Dexamethasone-(C21-phosphoramide)-[anti-EGFR], fludarabine-(C2-methylhydroxylphosphoramide)-[anti-IGF-1R], gemcitabine-(C2-methylhydroxylphosphoramide)-[anti-IGF-1R], or other covalent biopharmaceuticals neither bind selectively to nor do extensively diffuse passively across intact external surface membrane structures of normal cell populations residing within healthy tissues and organ systems. Such characteristics frequently are unrecognized and underestimated as one of the most important molecular mechanisms contributing to the greater margin of safety potentially afforded by dexamethasone-(C21-phosphoramide)-[anti-EGFR] and analogous covalent biopharmaceutical, including immunopharmaceuticals and immunochemotherapeutics.49-53

In the context of dexamethasone and other corticosteroid agents, minimizing their passive diffusion into normal cell populations within healthy tissues and organ systems substantially reduces this risk and severity of immunosuppression, compromised memory function, and neuropsychological side effects.194-196 Immunoglobulin (IgG MW = 150 kDa) or other biologically relevant molecular platforms that possess a relatively high molecular weight are of sufficient physical size to also effectively delay and reduce acute elimination burdens of pharmaceutical moieties on the process of renal glomerular filtration (MWCO = 60 kDa) or metabolism by biochemical pathways within hepatocytes. Reducing the rate and extent of renal excretion and hepatic metabolism of the dexamethasone moiety also in effect prolongs its intravascular pharmacokinetic profile in concert with substantially lowering the pharmaceutical moiety total volume of distribution. In this manner, total dosage requirements can potentially be reduced while simultaneously providing another variable that can improve in vivo margin of safety.

Corticosteroids are frequently a component of therapeutic protocols for hematopoietic neoplastic conditions in addition to autoimmune disease and severe inflammatory responses. In clinical oncology, corticosteroids have additional utility for decreasing general inflammation and tissue edema associated with burdens from expanding neoplastic lesions (eg, central nervous system) and for reducing the severity of general morbidty and inappetence. Given this perspective, dexamethasone-(C21-phosphoramide)-[IgG] represents a prototypical covalent immunopharmaceutical that potentially has a wide range of clinically relevant applications. The molecular mechanisms of action for corticosteroid class of pharmaceuticals directly correlate with their effectiveness as a significant “cornerstone” class of therapeutic agents for leukemia and lymphoma,197-199 especially for conditions of multiple myeloma. Although corticosteroids are commonly administrated for the therapeutic management of lymphoma,200 CLL,201,202 and acute lymphoblastic leukemia,203-205 the molecular design, organic chemistry synthesis reaction schemes, and the analysis of the antineoplastic cytotoxic potencies of covalent biocorticosteroids with selective antineoplastic cytotoxic efficacy against leukemia and lymphoma have not previously been described extensively. Covalent milatuzumab–dexamethasone has, however, been incorporated into liposomes to facilitate selective targeted delivery for therapeutic purposes against multiple myeloma and non-Hodgkin’s lymphoma when classified as CD74+ B-cell malignancies.201 The multiphase organic chemistry reaction scheme used in the synthesis of dexamethasone-(C21-phosphoramide)-[anti-EGFR] can potentially serve as a template guide for producing a modest array of covalent biotherapeutics that contain different corticosteroid/steroid-based moieties or other high molecular weight and biologically relevant molecular platforms besides anti-EGFR monoclonal immunoglobulin. Prednisone-(C21-phosphoramide)-[anti-CD19], prednisolone-(C21-phosphoramide)-[anti-CD20], and betamethasone-(C21-phosphoramide)-[anti-CD52] represent prototypical covalent immunopharmaceuticals that can be synthesized for such purposes utilizing dexamethasone-(C21-phosphoramide)-[anti-EGFR] as a reference template for designing their molecular structure and organic chemistry reactions for multiphase synthesis schemes. Conceptually, the molecular design and the multiphase organic chemistry reaction scheme described could therefore similarly be implemented for the synthesis of steroid hormone-based immunopharmaceuticals that contain agonist or antagonist analogs of estrogen/estriadiol, androgen/testosterone, or progesterone functioning as pharmaceutical moieties with applicability relevant to steroid-dependent neoplasia or steroid-responsive disease states. Molecular platforms that can potentially facilitate selective targeted delivery of dexamethasone or other corticosteroids relevant to CLL include monoclonal immunoglobulin, or ligands with selective binding avidity for CCR7, CXCR5, CD120a (TNFR1), CD19, CD20, and CD52 found on membrane exterior surfaces. Similarly, membrane sites potentially effective for selective targeted pharmaceutical moiety delivery for AML include CD7, CD33, CD44, CD47, CD123 (IL-31), CLL-1, and survivin.

Disclosure

The investigators and authors have no material, financial, or personal relationships external to College of Veterinary Medicine or Mississippi State University that would represent a conflict of interest in a manner that might bias the factual
and ethical content of the published article. The authors report no conflicts of interest in this work.

References


203. Domenech C, Suciu S, De Moerloose B, et al. Dexamethasone (6 mg/m²/day) and prednisolone (60 mg/m²/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica. 2014;99(7):1220–1227.
